藥明生物(02269.HK)配售4650萬股一級配售股份 淨籌39.29億港元
格隆匯11月1日丨藥明生物(02269.HK)公佈,於10月31日,配售代理與公司訂立一級配售協議,據此,配售代理向目前預期不少於六名的獨立專業、機構及╱或其他投資者按悉數包銷基準及每股85.00港元(較收市價每股92.50港元折讓約8.11%)的價格配售4650萬股一級配售股份。
假設於公告日期至一級配售完成公司已發行股本不會發生任何變動,4650萬股一級配售股份相當於(i)公司於公告日期現有已發行股本約3.73%;及(ii)公司經配發及發行一級配售股份擴大的已發行股本約3.60%。一級配售股份的總面值將為1,162.5美元。
公告稱,所得款項淨額將約為39.29億港元及每股一級配售股份的淨價將約為84.80港元。公司擬將一級配售的所得款項淨額用於支持其疫苗及微生物產品開發以及繼續進行全球產能擴張,包括其位於美國、歐洲及中國的設施,以滿足集團客户日益增長的需求。
此外,於10月31日,董事會獲公司的其中一名控股股東Biologics Holdings知會,其已與配售代理訂立二級配售協議,據此,配售代理按每股85.00港元的價格向獨立第三方配售Biologics Holdings持有的4650萬股二級配售股份,相當於公司於公告日期已發行股本約3.73%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.